Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34− and immature CD34+ cells

Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34− and immature CD34+ cells

Abstract Accumulation in target cells is an essential pharmacokinetic step of targeted therapies. Tyrosine Kinase Inhibitors (TKI) against the BCR-ABL fusion protein in Chronic Phase-Chronic Myeloid Leukaemia (CP-CML) cells constitute a unique model in terms of efficacy, specificity, and in vivo dem...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Marc G. Berger, Benjamin Lebecque, Thomas Tassin, Louis-Thomas Dannus, Juliette Berger, Mélanie Soucal, Agnès Guerci, Pascale Cony-Makhoul, Hyacinthe Johnson, Gabriel Etienne, Denis Guyotat, Marie-Claude Gagnieu, Bruno Pereira, Sandrine Saugues, Olivier Tournilhac, Eric Hermet, Céline Bourgne
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Medicine
R
Science
Q
Accès en ligne:https://doaj.org/article/dba1f40c656e42c3b03434ba4b592551
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/dba1f40c656e42c3b03434ba4b592551

Documents similaires